The HYPERFlax trial for determining the anti-HYPERtensive effects of dietary flaxseed in newly diagnosed stage 1 hypertensive patients: study protocol for a randomized, double-blinded, controlled clinical trial

Trials

Grant N Pierce¹  Brian Penner²  Stephanie PB Caligiuri¹ 

[1] Department of Physiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, MB R3E 0J9, Canada;Department of Internal Medicine, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, MB R3E 0J9, Canada

关键词: Alpha linolenic acid;    Nutrition;    Blood pressure;    Flaxseed;    Hypertension;   

Others  :  802704
DOI  :  10.1186/1745-6215-15-232

 received in 2014-01-14, accepted in 2014-05-27,  发布年份 2014

【 摘 要 】

Background

In 2013 the World Health Organization deemed hypertension as a global crisis as it is the leading risk factor attributed to global mortality. Therefore, there is a great need for effective alternative treatment strategies to combat a condition that affects 40% of adults worldwide. Recently, the FlaxPAD Trial observed a significant reduction in systolic and diastolic blood pressure in hypertensive patients with peripheral arterial disease that consumed 30 g of milled flaxseed per day for one year. However, these patients were already on anti-hypertensive medication. Therefore, there is a need to assess if dietary flaxseed can effectively reduce blood pressure in the absence of peripheral arterial disease and anti-hypertensive medication in newly diagnosed hypertensive patients.

Methods/Design

The HYPERFlax Trial is a parallel, superiority, phase II/III, randomized, double-blinded, controlled clinical trial. St. Boniface Hospital and the Health Sciences Centre of Winnipeg, Canada, will recruit 100 participants newly diagnosed with stage 1 hypertension who have yet to be administered anti-hypertensive medication. Participants will be randomly allocated with a 1:1 ratio into a flaxseed or control group and provided food products to consume daily for six months. At baseline, two, four, and six months, participant assessments will include the primary outcome measure, averaged automated blood pressure, and secondary measures: 24-hour food recall, international physical activity questionnaire, anthropometrics, and blood and urine sampling for biochemical analysis. Plasma will be assessed for lipids, metabolomics profiling, and molecules that regulate vascular tone. Urine will be collected for metabolomics profiling. With an estimated dropout rate of 20%, the trial will have a power of 0.80 to detect differences between groups and across time, out of an effect size of 0.7 (SD) at an α level of 0.05.

Discussion

This trial will determine if dietary flaxseed is efficacious over six months as an anti-hypertensive therapy in subjects newly diagnosed with hypertension. If flaxseed can effectively reduce blood pressure as a monotherapy, then flaxseed will provide individuals on a global basis with a cost-effective food-based strategy to control hypertension.

Trial registration

NCT01952340, Registered 24 September 2013.

【 授权许可】

   
2014 Caligiuri et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: A Global Brief on Hypertension: Silent killer, Global Public Health Crisis, WHO/DCO/WHD/2013. 2nd edition. Geneva, Switzerland: World Health Organization; 2013.
• [2]Bazzano LA, Green T, Harrison TN, Reynolds K: Dietary approaches to prevent hypertension. Curr Hypertens Rep 2013, 6:694-702.
• [3]Dupasquier CM, Weber AM, Ander BP, Rampersad PP, Steigerwald S, Wigle JT, Mitchell RW, Kroeger EA, Gilchrist JS, Moghadasian MM, Lukas A, Pierce GN: Effects of dietary flaxseed on vascular contractile function and atherosclerosis during prolonged hypercholesterolemia in rabbits. Am J Physiol Heart Circ Physiol 2006, 291:H2987-H2996.
• [4]Dupasquier CM, Dibrov E, Kneesh AL, Cheung PK, Lee KG, Alexander HK, Yeganeh BK, Moghadasian MH, Pierce GN: Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am J Physiol Heart Circ Physiol 2007, 293:H2394-H2402.
• [5]Bassett CM, McCullough RS, Edel AL, Patenaude A, LaVallee RK, Pierce GN: The alpha-linolenic acid content of flaxseed can prevent the atherogenic effects of dietary trans fat. Am J Physiol Heart Circ Physiol 2011, 301:H2220-H2226.
• [6]Tomaz Pacheco J, Beltrame Daleprame J, Teles BG: Impact of dietary flaxseed (linum usitatissimum) supplementation on biochemical profile in healthy rats. Nutr Hosp 2011, 26:798-802.
• [7]Park JB, Velasquez MT: Potential effects of lignan-enriched flaxseed powder on bodyweight, visceral fat, lipid profile, and blood pressure in rats. Fitoterapia 2012, 83:941-946.
• [8]Rodriguez-Leyva D, Weighell W, Edel AL, Lavallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN: Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension 2013, 62:1081-1089.
• [9]Hypertension Canada: The 2013 CHEP Recommendations 2013. http://www.hypertension.ca/chep webcite
• [10]Aliani M, Ryland D, Pierce GN: Effect of flax addition on the flavor profile and acceptability of bagels. J Food Sci 2012, 77:S62-S70.
• [11]Aliani M, Ryland D, Pierce GN: Effect of flax addition on the flavor profile of muffins and snack bars. Food Res Int 2011, 44:2489.
• [12]DeFelice A, Willard J, Lawrence J, Hung J, Gordon MA, Karkowsky A, Targum S, Throckmorton DC, Girton J, Stertz B, Glasser SP, Lipicky RJ: The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis. J Hum Hypertens 2008, 22:659-668.
• [13]Raper N, Perloff B, Ingwersen L, Steinfeldt L, Jaswinder A: An overview of USDA’s Dietary Intake Data System. J Food Comp Anal 2004, 17:545.
• [14]Kim Y, Park I, Kang M: Convergent validity of the international physical activity questionnaire (IPAQ): meta-analysis. Public Health Nutr 2013, 16:440-452.
• [15]Food and Drug Act: GRAS Notice 000280: Whole and Milled Flaxseed. Wangington, DC: US Food and Drug Administration; 2009.
• [16]Shultz TD, Bonorden WR, Seaman WR: Effect of short-term flaxseed consumption on lignan and sex hormone metabolism in men. Nutr Res 1991, 11:1089-1100.
• [17]Frische EJ, Hutchins AM, Martini MC, Thomas W, Slavin JL: Effect of flaxseed and wheat bran on serum hormones and lignan excretion in premenopausal women. J Am Coll Nutr 2003, 22:550-554.
• [18]Faintuch J, Horie LM, Barbeiro HV, Barbeiro DF, Soriano FG, Ishida RK, Cecconello I: Systemic inflammation in morbidly obese subjects: response to oral supplementation with alpha-linolenic acid. Obes Surg 2007, 17:341-347.
• [19]Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B: The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90:1390-1397.
• [20]Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, Szapary PO: Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 2008, 27:65-74.
• [21]Orcheson LJ, Rickard SE, Seidl MM, Thompson LU: Flaxseed and its mammalian lignan precursor cause a lengthening or cessation of estrous cycling in rats. Cancer Lett 1998, 125:69-76.
• [22]Chen J, Tan KP, Ward WE, Thompson LU: Exposure to flaxseed or its purified lignan during suckling inhibits chemically induced rat mammary tumorigenesis. Exp Biol Med (Maywood) 2003, 228:951-958.
• [23]Hemmings SJ, Barker L: The effects of dietary flaxseed on the Fischer 344 rat: I. development, behaviour, toxicity and the activity of liver gamma-glutamyltranspeptidase. Cell Biochem Funct 2004, 22:113-121.